Table 2 Case study summary
Domain | Low adherence (addressed < 19 recommendations) | High adherence (addressed ≥ 19 recommendations) | ||
|---|---|---|---|---|
McGrath, 2013 | Al-Omran, 2014 | McAlindon, 2017 | Chevalier, 2010 | |
Randomization (max. ✓) | ✓ | ✓ | ||
Blocking/stratification (max. ✓) | ✓ | ✓ | ✓ | ✓ |
Blinding (max. ✓✓✓) | ✓ | ✓ | ✓✓✓ | ✓✓✓ |
Expectations (max. ✓) | ||||
Washout periods/concomitant medications (max. ✓) | ✓ | ✓ | ✓ | ✓ |
Outcome reporting training (max. ✓) | ✓ | ✓ | ✓ | ✓ |
Comorbidities/ subphenotypes (max. ✓✓) | ✓✓ | ✓✓ | ✓✓ | ✓✓ |
Characterizing baseline disease (max. ✓) | ✓ | ✓ | ||
Selecting an index knee (max. ✓) | ✓ | ✓ | ||
Symptom-modifying interventions (max. ✓) | ✓ | ✓ | ||
Structure-modifying interventions (max. ✓) | ✓ | ✓ | ✓ | ✓ |
Trial interventions (max. ✓) | ✓ | ✓ | ||
Trial outcome measures (max. ✓✓) | ✓ | ✓✓ | ✓✓ | ✓✓ |
Patient-reported outcome measures (max. ✓) | ✓ | ✓ | ✓ | |
Objective outcome measures (max. ✓) | ✓ | ✓ | ||
Structural outcome measures (max. ✓✓✓) | ✓ | ✓ | ✓✓✓ | ✓ |
Biochemical biomarkers (max. ✓) | ✓ | |||
Reporting (max. ✓✓) | ✓ | ✓✓ | ✓✓ | |
Total number of addressed recommendations | 12 | 11 | 24 | 19 |